LAGIPRA peptide TFA is a long-acting GIP1R agonist. It improves insulin sensitivity by enhancing glucose processing and reducing circulating branched-chain amino acids (BCAA) and keto acids. LAGIPRA peptide TFA shows potential for research in type 2 diabetes.
Target:
IGF-1R
* VAT and and shipping costs not included. Errors and price changes excepted
